You are here

NIH Funding Opportunity: RFA-DA-17-020; Nicotinic Immune Modulation in the Presence of HIV-1 Infection (R01)

Tuesday, October 25, 2016

Nicotinic Immune Modulation in the Presence of HIV-1 Infection (R01)
(RFA-DA-17-020)
National Institute on Drug Abuse
Application Receipt Date(s): January 17, 2017 by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • The FOA encourages the submission of research project applications to determine nicotine’s modulatory effects on peripheral and central immune system functions in the presence of HIV-1 infection.  Specifically, NIDA is particularly interested in projects exploring the ability of nicotine to produce anti-inflammatory and protective effects, and the translational potential of the new knowledge in attenuating HIV-induced pathologies and HIV-associated CNS complications such as neurological/cognitive disorders.